The 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) was held in London, UK, from December 10 to 12. As a top-tier academic platform focusing on cutting-edge research and clinical practice in tumor immunology, the congress gathered world-class experts, scholars, and industry elites to exchange insights. At the congress, Juncell Therapeutics presented for the first time the Phase I clinical data of GC101 TIL for the treatment of advanced late-line non-small cell lung cancer (NSCLC). This is not only the world's first clinical study of TIL therapy without high-intensity lymphodepletion chemotherapy or IL-2 administration for lung cancer, but also the first registered clinical study in China to publicly disclose data in this field.

Juncell Therapeutics' GC101 demonstrated outstanding efficacy in the treatment of advanced NSCLC: in advanced patients with a median of three prior lines of therapy, it achieved an objective response rate (ORR) of 41.7% and a disease control rate (DCR) of 66.7%.

Abstract Number:  80P

Abstract Title:  A Phase I Trial of Optimized Autologous Tumor-Infiltrating Lymphocyte Therapy Without Exogenous IL-2 in Patients with Advanced Non-Small Cell Lung Cancer

Principal Investigator:  Professor Jianming Xu

Research Institution:  Chinese PLA General Hospital

Poster Presentation Time:  Dec.10-Dec.12, 2025